*" or "Cyclooxygenase 2 inhibitor*" or "Cyclooxygenase inhibitor*" or "Cyclo-oxygenase inhibitor*" or Dapsone or Dexibuprofen or Dexketoprofen or Diclofenac or Diflunisal or Dipyrone or Droxicam or Epirizole or Ethenzamide or Etodolac or Etoricoxib or Faislamine or Fenbufen or Fenoprofen or "Flufenamic acid" or Flunoxaprofen or Flurbiprofen or "Glycyrrhizic Acid" or Ibuprofen or Ibuproxam or Indomethacin
[Efficacy and tolerability of flunoxaprofen in the treatment of rheumatoid arthritis. A cross-over clinical study using naproxen]. The efficacy and safety of the new non-steroidal antiinflammatory drug flunoxaprofen were compared with those of naproxen in a cross over clinical study in patients with classical or definite rheumatoid arthritis (RA). Twenty female out-patients in the active phase of the disease were randomly assigned to one of the two groups studied; one group (A: 10 patients, mean age 51 years) received flunoxaprofen 400 mg/day p.o. for 30 days, followed by a 7-day wash-out period before starting the second treatment, with naproxen 500 mg/day p.o. for 30 days. Another group (B: 10 patients, mean age 58 years) received naproxen before flunoxaprofen and followed the same schedule
[Non-specific vaginitis and topical treatment. Comparison of flunoxaprofen and benzydamine]. The efficacy and tolerability of a new NSAID-flunoxaprofen-have been evaluated in patients suffering from non specific vaginitis, by topical application for 20 days (vaginal washings with water solution of the preparation). The activity of flunoxaprofen has been compared with that of benzidamine with regard to normalization of bacterial vaginal flora, taking into consideration the increase of Döderlein bacillus. A remarkable significant improvement of all the symptoms has been observed in the group of patients treated with flunoxaprofen with respect to that receiving benzidamine; moreover 57.9% of the subjects treated with flunoxaprofen showed a significant increase of Döderlein bacillus while